NewsBenzingaXRP to Drop Below $1? Crypto Analyst Warns Losing This Key Support May Intensify Selling Pressure XRP to Drop Below $1? Crypto Analyst Warns Losing This Key Support May Intensify Selling Pressure Benzinga 2026.10.26 06:18 (GMT+0) Open on Benzinga Other news Michael Burry Backs Ken Griffin on AI Bubble Concerns, Says GPU Overcapacity Warning Is Obvious to Anyone With a ‘Working Brain Cell’ Honeywell Technologies Debuts Forge Plant Cognition At Dangote’s Lekki Refinery, Estimating More Than 29 Cents A Barrel In Operational Benefit, Or Over $60M Per Year At Full Capacity Iran Hits Back At Marco Rubio’s ‘Pirates of the Caribbean’ Remark, Reminds Him Trump Proudly Said US Was ‘Sort of Like Pirates’ Robert Reich Says Elon Musk’s SpaceX and Starlink Should Become Publicly Owned, Musk Fires Back: ‘Stealing Companies Is a Serious Crime' Bristol Myers Squibb, SystImmune’s Iza-Bren Hits Primary Endpoint In Phase 3 PANKU-Lung01 Interim Analysis, Median PFS 11.1 Versus 5.7 Months (HR 0.40) Over Platinum Chemotherapy In EGFR-Mutated NSCLC Reported Saturday, GSK’s Jemperli Monotherapy Shows Generally Consistent Safety, With Serious Adverse Reactions In 20% And Discontinuations In 3%, Alongside 76% Complete Response In Phase II AZUR-1 MSI-H/dMMR Rectal Cancer Trial
Michael Burry Backs Ken Griffin on AI Bubble Concerns, Says GPU Overcapacity Warning Is Obvious to Anyone With a ‘Working Brain Cell’
Honeywell Technologies Debuts Forge Plant Cognition At Dangote’s Lekki Refinery, Estimating More Than 29 Cents A Barrel In Operational Benefit, Or Over $60M Per Year At Full Capacity
Iran Hits Back At Marco Rubio’s ‘Pirates of the Caribbean’ Remark, Reminds Him Trump Proudly Said US Was ‘Sort of Like Pirates’
Robert Reich Says Elon Musk’s SpaceX and Starlink Should Become Publicly Owned, Musk Fires Back: ‘Stealing Companies Is a Serious Crime'
Bristol Myers Squibb, SystImmune’s Iza-Bren Hits Primary Endpoint In Phase 3 PANKU-Lung01 Interim Analysis, Median PFS 11.1 Versus 5.7 Months (HR 0.40) Over Platinum Chemotherapy In EGFR-Mutated NSCLC
Reported Saturday, GSK’s Jemperli Monotherapy Shows Generally Consistent Safety, With Serious Adverse Reactions In 20% And Discontinuations In 3%, Alongside 76% Complete Response In Phase II AZUR-1 MSI-H/dMMR Rectal Cancer Trial
